Robert Dantzer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2107303/publications.pdf

Version: 2024-02-01

341 papers	38,257 citations	2802 94 h-index	3261 185 g-index
356 all docs	356 docs citations	356 times ranked	26880 citing authors

#	Article	IF	Citations
1	Neutralizing interleukin-6 in tumor-bearing mice does not abrogate behavioral fatigue induced by Lewis lung carcinoma. Behavioural Brain Research, 2022, 417, 113607.	2.2	3
2	Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission. Molecular Psychiatry, 2022, 27, 831-839.	7.9	5
3	Peripheral and central kynurenine pathway abnormalities in major depression. Brain, Behavior, and Immunity, 2022, 101, 136-145.	4.1	46
4	Evolutionary Aspects of Infections: Inflammation and Sickness Behaviors. Current Topics in Behavioral Neurosciences, 2022, , 1-14.	1.7	3
5	Love and fear: A special issue. Comprehensive Psychoneuroendocrinology, 2022, , 100151.	1.7	1
6	Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort. Journal of Psychiatric Research, 2021, 143, 534-542.	3.1	12
7	Inflammation and Depression: Is Immunometabolism the Missing Link?. , 2021, , 259-287.		3
8	Lipopolysaccharide does not alter behavioral response to successive negative contrast in mice. Psychopharmacology, 2021, 238, 691-697.	3.1	1
9	Love and fear in the times of sickness. Comprehensive Psychoneuroendocrinology, 2021, 6, 100032.	1.7	11
10	Inhibition of Tryptophan Catabolism Is Associated With Neuroprotection During Zika Virus Infection. Frontiers in Immunology, 2021, 12, 702048.	4.8	6
11	Inflammation, negative affect, and amyloid burden in Alzheimerâ€™s disease: Insights from the kynurenine pathway. Brain, Behavior, and Immunity, 2021, 95, 216-225.	4.1	19
12	Basic Concepts in Immunobiology. , 2021, , 1-24.		0
13	Microbiome-Gut-Brain Interactions in Neurodevelopmental Disorders: Focus on Autism and Schizophrenia. , 2021, , 258-291.		0
14	Immunotherapies for Depression. , 2021, , 139-163.		0
15	Inflammation, Sickness Behaviour and Depression. , 2021, , 109-138.		1
16	Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology, 2021, 131, 105295.	2.7	83
17	The Role of Adaptive and Innate Immunity in Alzheimerâ€™s Disease. , 2021, , 213-232.		0
18	Effectiveness of Immunotherapies for Psychotic Disorders. , 2021, , 96-108.		0

#	Article	IF	Citations
19	From Psychoneuroimmunology to Immunopsychiatry: An Historical Perspective. , 2021, , 25-50.		0
20	Transdiagnostic Features of the Immune System in Major Depressive Disorder, Bipolar Disorder and Schizophrenia. , 2021, , 309-335.		0
21	The Effect of Systemic Inflammation on Cognitive Function and Neurodegenerative Disease. , 2021, , 164-189.		0
22	Depression and the Adaptive Immune System. , 2021, , 292-308.		0
23	Neuroimmune mechanisms of cognitive impairment in a mouse model of Gulf War illness. Brain, Behavior, and Immunity, 2021, 97, 204-218.	4.1	9
24	Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. Brain, Behavior, and Immunity, 2021, 98, 161-172.	4.1	6
25	Brain Perivascular Macrophages Do Not Mediate Interleukin-1-Induced Sickness Behavior in Rats. Pharmaceuticals, 2021, 14, 1030.	3.8	6
26	Neuronal Mitochondrial Dysfunction and Bioenergetic Failure in Inflammation-Associated Depression. Frontiers in Neuroscience, 2021, 15, 725547.	2.8	14
27	Kynurenine pathway metabolites selectively associate with impaired associative memory function in depression. Brain, Behavior, & Immunity - Health, 2020, 8, 100126.	2.5	5
28	Covid-19: An urgent need for a psychoneuroendocrine perspective. Comprehensive Psychoneuroendocrinology, 2020, 1-2, 100003.	1.7	1
29	Effect of immune activation on the kynurenine pathway and depression symptoms â€“ A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2020, 118, 514-523.	6.1	82
30	Toll-like receptor 4 mediates the development of fatigue in the murine Lewis Lung Carcinoma model independently of activation of macrophages and microglia. Psychoneuroendocrinology, 2020, 122, 104874.	2.7	7
31	Interleukin-10 resolves pain hypersensitivity induced by cisplatin by reversing sensory neuron hyperexcitability. Pain, 2020, 161, 2344-2352.	4.2	55
32	Covid-19: An Urgent Need For A Psychoneuroendocrine Perspective. Psychoneuroendocrinology, 2020, 116, 104703.	2.7	8
33	Microglia depletion fails to abrogate inflammation-induced sickness in mice and rats. Journal of Neuroinflammation, 2020, 17, 172.	7.2	42
34	CD3+ T cells are critical for the resolution of comorbid inflammatory pain and depression-like behavior. Neurobiology of Pain (Cambridge, Mass), 2020, 7, 100043.	2.5	24
35	Interleukin 6-independent metabolic reprogramming as a driver of cancer-related fatigue. Brain, Behavior, and Immunity, 2020, 88, 230-241.	4.1	23
36	Motivational changes that develop in a mouse model of inflammation-induced depression are independent of indoleamine 2,3 dioxygenase. Neuropsychopharmacology, 2019, 44, 364-371.	5.4	27

#	Article	IF	Citations
37	Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice. Molecular Psychiatry, 2019, 24, 1523-1532.	7.9	118
38	Interleukin-1 reduces food intake and body weight in rat by acting in the arcuate hypothalamus. Brain, Behavior, and Immunity, 2019, 81, 560-573.	4.1	15
39	Can Immunopsychiatry Help in Understanding the Basis of Sex Differences in Major Depressive Disorder?. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 606-607.	1.5	2
40	Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virusâ€“Related Head and Neck Cancer. International Journal of Tryptophan Research, 2019, 12, 117864691987250.	2.3	2
41	From Stress Sensitization to Microglial Priming and Vice Versa: A New Era of Research in Biological Psychiatry. Biological Psychiatry, 2019, 85, 619-620.	1.3	3
42	Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior. Psychopharmacology, 2019, 236, 2975-2982.	3.1	21
43	Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice. Pain, 2019, 160, 1459-1468.	4.2	57
44	The selenium-containing compound 3-((4-chlorophenyl)selanyl)-1-methyl-1H-indole reverses depressive-like behavior induced by acute restraint stress in mice: modulation of oxido-nitrosative stress and inflammatory pathway. Psychopharmacology, 2019, 236, 2867-2880.	3.1	42
45	Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder. Psychoneuroendocrinology, 2018, 89, 194-202.	2.7	20
46	Inflammation-induced motivational changes: perspective gained by evaluating positive and negative valence systems. Current Opinion in Behavioral Sciences, 2018, 22, 90-95.	3.9	27
47	Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression. Brain, Behavior, and Immunity, 2018, 67, 59-64.	4.1	40
48	Mechanisms of poststroke fatigue. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 287-293.	1.9	86
49	Immune-based strategies for mood disorders: facts and challenges. Expert Review of Neurotherapeutics, 2018, 18, 139-152.	2.8	72
50	Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling. Cancer Research, 2018, 78, 695-705.	0.9	33
51	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open, 2018, 8, e025333.	1.9	51
52	Cancer exosomes induce tumor innervation. Nature Communications, 2018, 9, 4284.	12.8	169
53	Disruption of microglia histone acetylation and protein pathways in mice exhibiting inflammation-associated depression-like symptoms. Psychoneuroendocrinology, 2018, 97, 47-58.	2.7	18
54	An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology, 2018, 96, 109-117.	2.7	11

#	Article	IF	Citations
55	Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies. Neuroscience and Biobehavioral Reviews, 2018, 92, 477-485.	6.1	90
56	Can cancerâ€related cognitive impairment be considered in isolation from other cancerâ€related symptoms?. Psycho-Oncology, 2018, 27, 2511-2512.	2.3	3
57	Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain interleukin-10 signaling. Neuropsychopharmacology, 2018, 43, 2597-2605.	5.4	83
58	Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiological Reviews, 2018, 98, 477-504.	28.8	613
59	The High Costs of Low-Grade Inflammation: Persistent Fatigue as a Consequence of Reduced Cellular-Energy Availability and Non-adaptive Energy Expenditure. Frontiers in Behavioral Neuroscience, 2018, 12, 78.	2.0	108
60	Resilience and immunity. Brain, Behavior, and Immunity, 2018, 74, 28-42.	4.1	143
61	Neuroimmune mechanisms of behavioral alterations in a syngeneic murine model of human papilloma virus-related head and neck cancer. Psychoneuroendocrinology, 2017, 79, 59-66.	2.7	26
62	Sleep disturbance and kynurenine metabolism in depression. Journal of Psychosomatic Research, 2017, 99, 1-7.	2.6	46
63	Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain. Brain, Behavior, and Immunity, 2017, 66, 94-102.	4.1	60
64	Pifithrin-Î¼ Prevents Cisplatin-Induced Chemobrain by Preserving Neuronal Mitochondrial Function. Cancer Research, 2017, 77, 742-752.	0.9	89
65	Lipopolysaccharide Alters Motivated Behavior in a Monetary Reward Task: a Randomized Trial. Neuropsychopharmacology, 2017, 42, 801-810.	5.4	96
66	Psychiatric Disorders and Inflammation. , 2017, , 767-784.		0
67	Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery. International Journal of Neuropsychopharmacology, 2016, 19, pyw028.	2.1	124
68	Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches. Current Topics in Behavioral Neurosciences, 2016, 31, 117-138.	1.7	168
69	Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression. Brain, Behavior, and Immunity, 2016, 56, 335-342.	4.1	65
70	Psychoneuroimmune Phenomena: Neuroimmune Interactions. , 2016, , 643-670.		1
71	Is there a role for immune-to-brain communication in schizophrenia?. Psychopharmacology, 2016, 233, 1559-1573.	3.1	134
72	Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain, Behavior, and Immunity, 2016, 53, 39-48.	4.1	136

#	Article	IF	Citations
73	Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression. Behavioural Brain Research, 2016, 297, 241-250.	2.2	22
74	The cortisol awakening response at its best. Psychoneuroendocrinology, 2016, 63, 412-413.	2.7	2
75	Microglia Transcriptome Changes in a Model of Depressive Behavior after Immune Challenge. PLoS ONE, 2016, 11, e0150858.	2.5	35
76	Differential Transcriptome Networks between IDO1-Knockout and Wild-Type Mice in Brain Microglia and Macrophages. PLoS ONE, 2016, 11, e0157727.	2.5	15
77	Exercise, inflammation, and fatigue in cancer survivors. Exercise Immunology Review, 2016, 22, 82-93.	0.4	80
78	Advancing the understanding of behaviors associated with Bacille Calmette GuÃ©rin infection using multivariate analysis. Brain, Behavior, and Immunity, 2015, 44, 176-186.	4.1	10
79	Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice. Brain, Behavior, and Immunity, 2015, 46, 147-153.	4.1	40
80	Analytical workflow profiling gene expression in murine macrophages. Journal of Bioinformatics and Computational Biology, 2015, 13, 1550010.	0.8	8
81	Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology, 2015, 62, 54-58.	2.7	80
82	Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain, Behavior, and Immunity, 2015, 46, 55-59.	4.1	162
83	Mechanisms of chemotherapy-induced behavioral toxicities. Frontiers in Neuroscience, 2015, 9, 131.	2.8	133
84	Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology, 2015, 52, 200-211.	2.7	106
85	Putative Neuroprotective and Neurotoxic Kynurenine Pathway Metabolites Are Associated with Hippocampal and Amygdalar Volumes in Subjects with Major Depressive Disorder. Neuropsychopharmacology, 2015, 40, 463-471.	5.4	199
86	Elevated Levels of Plasma Phenylalanine in Schizophrenia: A Guanosine Triphosphate Cyclohydrolase-1 Metabolic Pathway Abnormality?. PLoS ONE, 2014, 9, e85945.	2.5	19
87	Voluntary Wheel Running Does Not Affect Lipopolysaccharide-Induced Depressive-Like Behavior in Young Adult and Aged Mice. NeuroImmunoModulation, 2014, 21, 52-63.	1.8	26
88	The neuroimmune basis of fatigue. Trends in Neurosciences, 2014, 37, 39-46.	8.6	254
89	Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?. Journal of Neural Transmission, 2014, 121, 925-932.	2.8	114
90	Lipopolysaccharide Reduces Incentive Motivation While Boosting Preference for High Reward in Mice. Neuropsychopharmacology, 2014, 39, 2884-2890.	5.4	66

#	Article	IF	Citations
91	Activation of lung toll-like receptors does not exacerbate sickness responses to lipopolysaccharide in mice. Brain, Behavior, and Immunity, 2014, 38, 211-219.	4.1	1
92	Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. Frontiers in Pharmacology, 2014, 5, 8.	3.5	25
93	NMDA Receptor Blockade by Ketamine Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior in C57BL/6J Mice. Neuropsychopharmacology, 2013, 38, 1609-1616.	5.4	374
94	Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. Journal of Neuroinflammation, 2013, 10, 87.	7.2	109
95	Aging leads to prolonged duration of inflammation-induced depression-like behavior caused by Bacillus Calmette-GuÃ©rin. Brain, Behavior, and Immunity, 2013, 32, 63-69.	4.1	46
96	Effects of voluntary wheel running on LPS-induced sickness behavior in aged mice. Brain, Behavior, and Immunity, 2013, 29, 113-123.	4.1	38
97	Psychoneuroimmune Phenomena: Neuroimmune Interactions. , 2013, , 527-554.		1
98	Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX3CR1)-deficient mice. Brain, Behavior, and Immunity, 2013, 31, 134-142.	4.1	117
99	Mood Disorders and Immunity. , 2013, , 167-209.		1
100	G Protein-Coupled Receptor Kinase 6 Acts as a Critical Regulator of Cytokine-Induced Hyperalgesia by Promoting Phosphatidylinositol 3-Kinase and Inhibiting p38 Signaling. Molecular Medicine, 2012, 18, 556-564.	4.4	23
101	Depression and Inflammation: An Intricate Relationship. Biological Psychiatry, 2012, 71, 4-5.	1.3	99
102	Translational approaches to treatment-induced symptoms in cancer patients. Nature Reviews Clinical Oncology, 2012, 9, 414-426.	27.6	115
103	Acute hypoglycemia causes depressive-like behaviors in mice. Metabolism: Clinical and Experimental, 2012, 61, 229-236.	3.4	33
104	Alcoholism and inflammation: Neuroimmunology of behavioral and mood disorders. Brain, Behavior, and Immunity, 2011, 25, S13-S20.	4.1	115
105	Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: A possible mechanism for AIDS comorbid depression. Brain, Behavior, and Immunity, 2011, 25, 1569-1575.	4.1	81
106	The associations of adiposity, physical activity and inflammation with fatigue in older adults. Brain, Behavior, and Immunity, 2011, 25, 1482-1490.	4.1	42
107	Voluntary Wheel Running Reverses Age-Induced Changes in Hippocampal Gene Expression. PLoS ONE, 2011, 6, e22654.	2.5	61
108	Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology, 2011, 36, 426-436.	2.7	626

#	Article	IF	Citations
109	GRK2 in sensory neurons regulates epinephrine-induced signalling and duration of mechanical hyperalgesia. Pain, 2011, 152, 1649-1658.	4.2	43
110	Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. Journal of Neuroinflammation, 2011, 8, 12.	7.2	127
111	Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. Journal of Neuroinflammation, 2011, 8, 179.	7.2	54
112	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. Journal of Neuroinflammation, 2011, 8, 88.	7.2	40
113	Cytokineâ€induced Hormone Resistance. , 2011, , 254-258.		0
114	Microglial/macrophage GRK2 determines duration of peripheral IL-1Î²-induced hyperalgesia: Contribution of spinal cord CX3CR1, p38 and IL-1 signaling. Pain, 2010, 150, 550-560.	4.2	85
115	Ten years of Nature Reviews Neuroscience: insights from the highly cited. Nature Reviews Neuroscience, 2010, 11, 718-726.	10.2	32
116	CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-Î±: relationship to CNS immune responses and depression. Molecular Psychiatry, 2010, 15, 393-403.	7.9	546
117	Un sustrato biolÃ³gico para los trastornos somatomorfos. , 2010, , 61-70.		0
118	Low Nociceptor GRK2 Prolongs Prostaglandin E₂Hyperalgesia via Biased cAMP Signaling to Epac/Rap1, Protein Kinase CÎµ, and MEK/ERK. Journal of Neuroscience, 2010, 30, 12806-12815.	3.6	85
119	Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. Journal of Neuroinflammation, 2010, 7, 93.	7.2	166
120	LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-Î³-independent manner by a JNK signaling pathway in primary murine microglia. Brain, Behavior, and Immunity, 2010, 24, 201-209.	4.1	72
121	Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2,3-dioxygenase. Brain, Behavior, and Immunity, 2010, 24, 1249-1253.	4.1	17
122	Central Administration of Lipopolysaccharide Induces Depressive-like Behavior in Vivo and Activates Brain Indoleamine 2,3 Dioxygenase In Murine Organotypic Hippocampal Slice Cultures. Journal of Neuroinflammation, 2010, 7, 43.	7.2	105
123	8. Que faire du comportement dans les sciences du comportementÂ?. , 2010, , 197-208.		0
124	Hypoglycemia causes depressiveâ€like behaviors in mice. FASEB Journal, 2010, 24, lb380.	0.5	0
125	8. Que faire du comportement dans les sciences du comportementÂ?. , 2010, , 197-208.		0
126	Induction of IDO by Bacille Calmette-Guèrin Is Responsible for Development of Murine Depressive-Like Behavior. Journal of Immunology, 2009, 182, 3202-3212.	0.8	279

#	Article	IF	Citations
127	Editorial. Psychoneuroendocrinology, 2009, 34, 1.	2.7	44
128	The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFÎ±-induced sickness behavior. Psychopharmacology, 2009, 201, 549-556.	3.1	40
129	Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Molecular Psychiatry, 2009, 14, 511-522.	7.9	1,084
130	Interferon-Î³ and Tumor Necrosis Factor-Î± Mediate the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-Like Behavior in Mice in Response to Bacillus Calmette-GuÃ©rin. Journal of Neuroscience, 2009, 29, 4200-4209.	3.6	441
131	Cytokine, Sickness Behavior, and Depression. Immunology and Allergy Clinics of North America, 2009, 29, 247-264.	1.9	606
132	From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 2008, 9, 46-56.	10.2	5,599
133	Uncoupling of interleukinâ€6 from its signalling pathway by dietary nâ€3â€polyunsaturated fatty acid deprivation alters sickness behaviour in mice. European Journal of Neuroscience, 2008, 28, 1877-1886.	2.6	85
134	Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology. Cellular Immunology, 2008, 252, 91-110.	3.0	202
135	Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration. Journal of Neuroimmunology, 2008, 200, 90-99.	2.3	104
136	In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1Î² in the murine brain. Brain, Behavior, and Immunity, 2008, 22, 234-244.	4.1	95
137	Autistic childrens: A neuroimmune perspective. Brain, Behavior, and Immunity, 2008, 22, 804-805.	4.1	11
138	Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain, Behavior, and Immunity, 2008, 22, 1087-1095.	4.1	142
139	Aging Exacerbates Depressive-like Behavior in Mice in Response to Activation of the Peripheral Innate Immune System. Neuropsychopharmacology, 2008, 33, 2341-2351.	5.4	267
140	Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1Î². American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E709-E718.	3.5	25
141	Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. Journal of Cell Science, 2007, 120, 578-585.	2.0	66
142	A Biological Substrate for Somatoform Disorders: Importance of Pathophysiology. Psychosomatic Medicine, 2007, 69, 850-854.	2.0	76
143	Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 2007, 21, 153-160.	4.1	1,125
144	Expression and Action of Cytokines in the Brain: Mechanisms and Pathophysiological Implications. , 2007, , 271-280.		4

#	Article	IF	Citations
145	Cytokines, Sickness Behavior, and Depression. , 2007, , 281-318.		11
146	Crosstalk between Insulin-like Growth Factors and Pro-inflammatory Cytokines. , 2007, , 171-191.		1
147	Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology, 2007, 32, 516-531.	2.7	381
148	TNFÎ±-induced sickness behavior in mice with functional 55ÂkD TNF receptors is blocked by central IGF-I. Journal of Neuroimmunology, 2007, 187, 55-60.	2.3	54
149	Novel activity of an anti-inflammatory cytokine: IL-10 prevents TNFÎ±-induced resistance to IGF-I in myoblasts. Journal of Neuroimmunology, 2007, 188, 48-55.	2.3	33
150	INTRODUCTION TO IMMUNE SYSTEM EFFECTS ON NEURAL AND ENDOCRINE PROCESSES AND BEHAVIOR. , 2007, , 267-270.		0
151	Cytokine, Sickness Behavior, and Depression. Neurologic Clinics, 2006, 24, 441-460.	1.8	269
152	Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. Brain, Behavior, and Immunity, 2006, 20, 57-63.	4.1	66
153	Insulin-like growth factor-I enhances the biological activity of brain-derived neurotrophic factor on cerebrocortical neurons. Journal of Neuroimmunology, 2006, 179, 186-190.	2.3	57
154	C-Jun N-Terminal Kinase Mediates Tumor Necrosis Factor-Î± Suppression of Differentiation in Myoblasts. Endocrinology, 2006, 147, 4363-4373.	2.8	39
155	Social factors and individual vulnerability to chronic stress exposure. Neuroscience and Biobehavioral Reviews, 2005, 29, 67-81.	6.1	188
156	NFÎºB Activatesin vivothe Synthesis of Inducible Cox-2 in the Brain. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1047-1059.	4.3	73
157	Somatization: A psychoneuroimmune perspective. Psychoneuroendocrinology, 2005, 30, 947-952.	2.7	105
158	Pentoxifylline and insulin-like growth factor-I (IGF-I) abrogate kainic acid-induced cognitive impairment in mice. Journal of Neuroimmunology, 2005, 169, 50-58.	2.3	21
159	Bacille Calmetteâ€GuÃ©rin Inoculation Induces Chronic Activation of Peripheral and Brain Indoleamine 2,3â€Dioxygenase in Mice. Journal of Infectious Diseases, 2005, 192, 537-544.	4.0	95
160	IL-1Î²-Mediated Innate Immunity Is Amplified in the db/db Mouse Model of Type 2 Diabetes. Journal of Immunology, 2005, 174, 4991-4997.	0.8	82
161	Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15184-15189.	7.1	36
162	Inactivation of the Cerebral NFÎºB Pathway Inhibits Interleukin-1Î²-Induced Sickness Behavior and c-Fos Expression in Various Brain Nuclei. Neuropsychopharmacology, 2005, 30, 1492-1499.	5.4	118

#	Article	IF	Citations
163	A role of IL-1 in MPTP-induced changes in striatal dopaminergic and serotoninergic transporter binding: clues from interleukin-1 type I receptor-deficient mice. Molecular Brain Research, 2005, 136, 267-270.	2.3	6
164	Cellular distribution of interleukin-1Î±-immunoreactivity after MPTP intoxication in mice. Molecular Brain Research, 2005, 138, 156-163.	2.3	7
165	EuroConference on cytokines in the brain: Expression and action of cytokines in the brain and pathophysiological implicationsâ˜†. Brain, Behavior, and Immunity, 2005, 19, 263-267.	4.1	2
166	The taste of sickness: Lipopolysaccharide-induced finickiness in rats. Physiology and Behavior, 2005, 84, 437-444.	2.1	47
167	Mood Alterations During Interferon-Alfa Therapy in Patients With Chronic Hepatitis C. Journal of Clinical Psychiatry, 2005, 66, 1050-1057.	2.2	139
168	Tumor Necrosis Factor Î± Inhibits Insulin-Like Growth Factor I-Induced Hematopoietic Cell Survival and Proliferation. Endocrinology, 2004, 145, 3101-3105.	2.8	14
169	A Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms. NeuroImmunoModulation, 2004, 11, 279-292.	1.8	266
170	Proinflammatory Cytokine Impairment of Insulin-Like Growth Factor I-Induced Protein Synthesis in Skeletal Muscle Myoblasts Requires Ceramide. Endocrinology, 2004, 145, 4592-4602.	2.8	99
171	Immune Alterations Induced by Social Defeat Do Not Alter the Course of an On-Going BCG Infection in Mice. NeuroImmunoModulation, 2004, 11, 414-418.	1.8	5
172	IL-1Î² Impairs Insulin-Like Growth Factor I-Induced Differentiation and Downstream Activation Signals of the Insulin-Like Growth Factor I Receptor in Myoblasts. Journal of Immunology, 2004, 172, 7713-7720.	0.8	102
173	IL-1Î² Suppresses Prolonged Akt Activation and Expression of E2F-1 and Cyclin A in Breast Cancer Cells. Journal of Immunology, 2004, 172, 7272-7281.	0.8	21
174	Tumor Necrosis Factor Î± Inhibits Cyclin A Expression and Retinoblastoma Hyperphosphorylation Triggered by Insulin-like Growth Factor-I Induction of New E2F-1 Synthesis. Journal of Biological Chemistry, 2004, 279, 7438-7446.	3.4	29
175	Influence of the course of brain inflammation on the endogenous IL-1Î²/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmetteâ€“GuÃ©rin in Lewis rats. Journal of Neuroimmunology, 2004, 149, 22-30.	2.3	16
176	Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology, 2004, 29, 778-790.	2.7	48
177	Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. European Journal of Pharmacology, 2004, 500, 399-411.	3.5	600
178	Nuclear factor ÎºB nuclear translocation as a crucial marker of brain response to interleukin-1. A study in rat and interleukin-1 type I deficient mouse. Journal of Neurochemistry, 2004, 87, 1024-1036.	3.9	76
179	Cytokine Production by Spleen Cells after Social Defeat in Mice: Activation of T Cells and Reduced Inhibition by Glucocorticoids. Stress, 2004, 7, 55-61.	1.8	42
180	Interleukin-1Î² mediates the memory impairment associated with a delayed type hypersensitivity response to bacillus Calmetteâ€“GuÃ©rin in the rat hippocampus. Brain, Behavior, and Immunity, 2004, 18, 223-230.	4.1	41

#	Article	IF	Citations
181	Innate immunity at the forefront of psychoneuroimmunology. Brain, Behavior, and Immunity, 2004, 18, 1-6.	4.1	79
182	Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain, Behavior, and Immunity, 2004, 18, 205-213.	4.1	217
183	The rank assessed in a food competition test influences subsequent reactivity to immune and social challenges in mice. Brain, Behavior, and Immunity, 2004, 18, 468-475.	4.1	33
184	Conditioned taste aversion with lipopolysaccharide and peptidoglycan does not activate cytokine gene expression in the spleen and hypothalamus of mice. Brain, Behavior, and Immunity, 2004, 18, 186-200.	4.1	32
185	Mechanisms of Cytokine-Induced Sickness Behavior. , 2004, , 707-719.		0
186	Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation. Psychoneuroendocrinology, 2003, 28, 19-34.	2.7	46
187	Insulin-like growth factor-I and the cytokines IL-3 and IL-4 promote survival of progenitor myeloid cells by different mechanisms. Journal of Neuroimmunology, 2003, 135, 82-90.	2.3	17
188	Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?. Cancer, 2003, 97, 2919-2925.	4.1	460
189	Importance of fighting in the immune effects of social defeat. Physiology and Behavior, 2003, 80, 351-357.	2.1	41
190	Chronic psychosocial stress down-regulates central cytokines mRNA. Brain Research Bulletin, 2003, 62, 173-178.	3.0	77
191	Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neuroscience Letters, 2003, 349, 191-195.	2.1	64
192	Conditioned place aversion with interleukin-1Î² in mice is not associated with activation of the cytokine network. Brain, Behavior, and Immunity, 2003, 17, 110-120.	4.1	14
193	Cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 2003, 17, 112-118.	4.1	597
194	Cytokines and depression: The need for a new paradigm. Brain, Behavior, and Immunity, 2003, 17, 119-124.	4.1	241
195	Cytokine-Hormone Interactions: Tumor Necrosis Factor Î± Impairs Biologic Activity and Downstream Activation Signals of the Insulin-Like Growth Factor I Receptor in Myoblasts. Endocrinology, 2003, 144, 2988-2996.	2.8	98
196	Les inter-relations entre le systÃ¨me nerveux et le systÃ¨me immunitaire. SociÃ©tÃ© De Biologie Journal, 2003, 197, 81-88.	0.3	20
197	Cytokines and Sickness Behavior. Neurobiological Foundation of Aberrant Behaviors, 2003, , 129-146.	0.2	3
198	Age-Associated Loss of Bone Marrow Hematopoietic Cells Is Reversed by GH and Accompanies Thymic Reconstitution. Endocrinology, 2002, 143, 690-699.	2.8	78

#	Article	IF	Citations
199	Chronic Mild Stress in Mice Decreases Peripheral Cytokine and Increases Central Cytokine Expression Independently of IL-10 Regulation of the Cytokine Network. NeuroImmunoModulation, 2002, 10, 359-366.	1.8	44
200	Cytokines and depression: An update. Brain, Behavior, and Immunity, 2002, 16, 501-502.	4.1	24
201	Is it important to know about emotions in order to study emotions?. Behavioural Processes, 2002, 60, v-vii.	1.1	1
202	Cytokine-induced sickness behaviour: mechanisms and implications. Trends in Neurosciences, 2002, 25, 154-159.	8.6	843
203	IL-10 promotes survival of microglia without activating Akt. Journal of Neuroimmunology, 2002, 122, 9-19.	2.3	68
204	Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. Journal of Neuroimmunology, 2002, 125, 5-14.	2.3	123
205	Dual Effect of Central Injection of Recombinant Rat Interleukin-4 on Lipopolysaccharide-Induced Sickness Behavior in Rats. Neuropsychopharmacology, 2002, 26, 86-93.	5.4	38
206	Long-term modulation of glucose utilization by IL-1Î± and TNF-Î± in astrocytes: Na+pump activity as a potential target via distinct signaling mechanisms. Glia, 2002, 39, 10-18.	4.9	31
207	Age-Associated Loss of Bone Marrow Hematopoietic Cells Is Reversed by GH and Accompanies Thymic Reconstitution. Endocrinology, 2002, 143, 690-699.	2.8	36
208	Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Research, 2002, 62, 4746-56.	0.9	59
209	Cytokine-Induced Sickness Behavior: Where Do We Stand?. Brain, Behavior, and Immunity, 2001, 15, 7-24.	4.1	726
210	Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-Î± Treatments in Cancer Patients. Psychosomatic Medicine, 2001, 63, 376-386.	2.0	132
211	Central injection of interleukin-13 potentiates LPS-induced sickness behavior in rats. NeuroReport, 2001, 12, 3979-3983.	1.2	25
212	Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1Î² in the rat. Psychopharmacology, 2001, 154, 50-60.	3.1	125
213	Rat microglial cells secrete predominantly the precursor of interleukin-1Î² in response to lipopolysaccharide. European Journal of Neuroscience, 2001, 14, 609-617.	2.6	64
214	Tumor necrosis factorÎ± and insulin-like growth factor-I in the brain: Is the whole greater than the sum of its parts?. Journal of Neuroimmunology, 2001, 119, 151-165.	2.3	36
215	Effects of serotonin synthesis blockade on interleukin-1Î² action in the brain of rats. Brain Research, 2001, 915, 244-247.	2.2	19
216	How the immune and nervous systems interact during disease-associated anorexia. Nutrition, 2001, 17, 664-668.	2.4	66

#	Article	IF	Citations
217	Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology, 2001, 26, 797-808.	2.7	182
218	Stress, emotions and health: where do we stand?. Social Science Information, 2001, 40, 61-78.	1.6	8
219	Cytokineâ€induced Sickness Behavior: Mechanisms and Implications. Annals of the New York Academy of Sciences, 2001, 933, 222-234.	3.8	671
220	Cytokines in Clinical Psychiatry. American Journal of Psychiatry, 2001, 158, 1163-1163.	7.2	23
221	Interleukin-10 in the Brain. Critical Reviews in Immunology, 2001, 21, 23.	0.5	321
222	The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. European Journal of Neuroscience, 2000, 12, 4434-4446.	2.6	197
223	Role of interleukinâ€1Î² and tumour necrosis factorâ€Î± in lipopolysaccharideâ€induced sickness behaviour: a study with interleukinâ€1 type I receptorâ€deficient mice. European Journal of Neuroscience, 2000, 12, 4447-4456.	2.6	16
224	Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R93-R98.	1.8	187
225	Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy. Journal of Clinical Oncology, 2000, 18, 2143-2151.	1.6	270
226	A new concept in neurodegeneration: TNFÎ± is a silencer of survival signals. Trends in Neurosciences, 2000, 23, 175-180.	8.6	195
227	Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Autonomic Neuroscience: Basic and Clinical, 2000, 85, 60-65.	2.8	312
228	Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Autonomic Neuroscience: Basic and Clinical, 2000, 85, 127-132.	2.8	97
229	Cholecystokinin receptors do not mediate the suppression of food-motivated behavior by lipopolysaccharide and interleukin-1 beta in mice. Physiology and Behavior, 2000, 69, 325-331.	2.1	21
230	Role of IL-6 in cytokine-induced sickness behavior a study with IL-6 deficient mice. Physiology and Behavior, 2000, 70, 367-373.	2.1	204
231	Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. European Journal of Neuroscience, 2000, 12, 4447-4456.	2.6	109
232	The Immune-Endocrine Loop during Aging: Role of Growth Hormone and Insulin-Like Growth Factor-I. NeuroImmunoModulation, 1999, 6, 56-68.	1.8	51
233	Cytokines, Stress, and Depression. Advances in Experimental Medicine and Biology, 1999, 461, 317-329.	1.6	68
234	A new mechanism of neurodegeneration: A proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9879-9884.	7.1	189

#	Article	IF	Citations
235	Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. Journal of Neuroimmunology, 1999, 93, 194-202.	2.3	107
236	Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology, 1999, 24, 301-311.	2.7	162
237	Temporal and spatial relationships between lipopolysaccharide-induced expression of fos, interleukin-1 Î² and inducible nitric oxide synthase in rat brain. Neuroscience, 1999, 89, 535-548.	2.3	220
238	Mechanisms of the Behavioural Effects of Cytokines. Advances in Experimental Medicine and Biology, 1999, 461, 83-105.	1.6	81
239	Increased Sensitivity of Prediabetic Nonobese Diabetic Mouse to the Behavioral Effects of IL-1. Brain, Behavior, and Immunity, 1999, 13, 303-314.	4.1	16
240	Elevated Cyclin E Levels, Inactive Retinoblastoma Protein, and Suppression of the p27^{KIP1} Inhibitor Characterize Early Development of Promyeloid Cells into Macrophages. Molecular and Cellular Biology, 1999, 19, 6229-6239.	2.3	34
241	Central administration of insulin-like growth factor-1 inhibits lipopolysaccharide-induced sickness behavior in mice. NeuroReport, 1999, 10, 289-292.	1.2	51
242	Molecular Basis of Sickness Behaviora. Annals of the New York Academy of Sciences, 1998, 856, 132-138.	3.8	227
243	Insulin Growth Factorâ€Ł Inhibits Apoptosis in Hematopoietic: Progenitor Cells Implications in Thymic Aging^a. Annals of the New York Academy of Sciences, 1998, 840, 518-524.	3.8	49
244	Cytokines and Sickness Behavior. Annals of the New York Academy of Sciences, 1998, 840, 586-590.	3.8	237
245	Expression of the 75 kDA TNF receptor and its role in contact-mediated neuronal cell death. Molecular Brain Research, 1998, 62, 111-121.	2.3	21
246	Blockade of brain type II interleukin-1 receptors potentiates IL1Î²-induced anorexia in mice. Neuroscience Letters, 1998, 246, 101-104.	2.1	25
247	In Vivo and in Vitro Evidence for the Involvement of Tumor Necrosis Factor-Î± in the Induction of Leptin by Lipopolysaccharide*. Endocrinology, 1998, 139, 2278-2283.	2.8	159
248	Interleukin-1Î²-converting enzyme-deficient mice resist central but not systemic endotoxin-induced anorexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 274, R1829-R1833.	1.8	24
249	Brain type I but not type II IL-1 receptors mediate the effects of IL-1Î² on behavior in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 274, R735-R740.	1.8	16
250	Regulation of Myeloid Growth and Differentiation by the Insulin-Like Growth Factor I Receptor1. Endocrinology, 1997, 138, 362-368.	2.8	62
251	Hypersensitivity of lurcher mutant mice to the depressing effects of lipopolysaccharide and interleukin-1 on behaviour. NeuroReport, 1997, 8, 1119-1122.	1.2	11
252	Differential Effects of Lipopolysaccharide on Pup Retrieving and Nest Building in Lactating Mice. Brain, Behavior, and Immunity, 1997, 11, 107-118.	4.1	175

#	Article	IF	Citations
253	Defect in Interleukin-1Î² Secretion Prevents Sickness Behavior in C3H/HeJ Mice. Physiology and Behavior, 1997, 61, 873-878.	2.1	47
254	Systemic Capsaicin Pretreatment Fails to Block the Decrease in Food-Motivated Behavior Induced by Lipopolysaccharide and Interleukin-1 Î². Brain Research Bulletin, 1997, 42, 443-449.	3.0	46
255	Central Interleukin-1 Receptors as Mediators of Sickness. Annals of the New York Academy of Sciences, 1997, 823, 234-246.	3.8	28
256	Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology, 1997, 22, 1-11.	2.7	78
257	Individually distinctive odours represent individual conspecifics in rats. Animal Behaviour, 1997, 53, 935-944.	1.9	74
258	Regulation of Myeloid Growth and Differentiation by the Insulin-Like Growth Factor I Receptor. Endocrinology, 1997, 138, 362-368.	2.8	20
259	Mechanisms of action of cytokines on the central nervous system. Interaction with glucocorticoids. , 1997, , 1-13.		1
260	Adrenalectomy enhances pro-inflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Molecular Brain Research, 1996, 36, 53-62.	2.3	121
261	An endogenous 55 kDa TNF receptor mediates cell death in a neural cell line. Molecular Brain Research, 1996, 38, 222-232.	2.3	54
262	Effect of intracerebroventricular administration of vasopressin on stress-induced hyperthermia in rats. Physiology and Behavior, 1996, 60, 417-424.	2.1	35
263	Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. NeuroReport, 1996, 7, 1485-1488.	1.2	139
264	Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. NeuroReport, 1996, 7, 2823.	1.2	140
265	Growth Hormone, Growth Factors and Hematopoiesis. Hormone Research, 1996, 45, 38-45.	1.8	78
266	Cytokine Actions on Behavior. Neuroscience Intelligence Unit, 1996, , 117-144.	0.5	37
267	Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Research, 1995, 677, 171-176.	2.2	79
268	Endogenous glucocorticoids down regulate central effects of interleukin-1 Î² on body temperature and behaviour in mice. Brain Research, 1995, 702, 173-180.	2.2	46
269	Compared effects of cold ambient temperature and cytokines on macronutrient intake in rats. Physiology and Behavior, 1995, 57, 869-873.	2.1	59
270	Lipopolysaccharide and Interleukin-1 Depress Food-Motivated Behavior in Mice by a Vagal-Mediated Mechanism. Brain, Behavior, and Immunity, 1995, 9, 242-246.	4.1	205

#	Article	IF	Citations
271	Stress Downregulates Lipopolysaccharide-Induced Expression of Proinflammatory Cytokines in the Spleen, Pituitary, and Brain of Mice. Brain, Behavior, and Immunity, 1995, 9, 292-303.	4.1	101
272	Central nervous system control of sickness behavior. , 1994, , 152-182.		3
273	Competitive Reverse Transcriptase-Polymerase Chain Reaction Using a Synthetic Internal RNA Standard to Quantitate Transcripts for Leukocyte-Derived Hormones. NeuroImmunoModulation, 1994, 1, 33-41.	1.8	8
274	Ethological study of the effects of tetrahydroaminoacridine (THA) on social recognition in rats. Psychopharmacology, 1994, 114, 644-650.	3.1	36
275	Synergy between tumor necrosis factor Î± and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology, 1994, 19, 197-207.	2.7	180
276	Immunology discovers physiology. Veterinary Immunology and Immunopathology, 1994, 43, 157-165.	1.2	48
277	Expression of type I and type II interleukin-1 receptors in mouse brain. Molecular Brain Research, 1994, 27, 63-70.	2.3	130
278	Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Molecular Brain Research, 1994, 27, 157-162.	2.3	459
279	Reduction in food and water intake induced by microinjection of interleukin-1Î² in the ventromedial hypothalamus of the rat. Physiology and Behavior, 1994, 56, 1031-1036.	2.1	84
280	Social and individual recognition in rodents: Methodological aspects and neurobiological bases. Behavioural Processes, 1994, 33, 59-87.	1.1	187
281	A behaviorally active dose of lipopolysaccharide increases sensory neuropeptides levels in mouse spinal cord. Neuroscience Letters, 1994, 173, 205-209.	2.1	26
282	Molecular Identification of Two Types of Interleukin-1 Receptors in the Murine Pituitary Gland. Journal of Neuroendocrinology, 1993, 5, 213-219.	2.6	47
283	Central and peripheral prostaglandins are involved in sickness behavior in birds. Physiology and Behavior, 1993, 53, 127-131.	2.1	92
284	Sickness behavior in birds caused by peripheral or central injection of endotoxin. Physiology and Behavior, 1993, 53, 343-348.	2.1	96
285	Somatolactogens, Somatomedins, and Immunity. Journal of Dairy Science, 1993, 76, 2437-2450.	3.4	31
286	Vasopressin and behavior: from memory to olfaction. Regulatory Peptides, 1993, 45, 121-125.	1.9	33
287	Behavioral Effects of Cytokines: An Insight into Mechanisms of Sickness Behavior. Methods in Neurosciences, 1993, , 130-150.	0.5	58
288	Modulation of the behavioural effects of Interleukin-1 in mice by Nitric Oxide. NeuroReport, 1992, 3, 207-209.	1.2	27

#	Article	IF	Citations
289	Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate behavioral effects of interleukin-1 in rat. Brain Research Bulletin, 1992, 29, 897-900.	3.0	17
290	Effects of lipopolysaccharide on food-motivated behavior in the rat are not blocked by an interleukin-1 receptor antagonist. Neuroscience Letters, 1992, 145, 83-86.	2.1	62
291	Mechanisms of the Behavioral Effects of Interleukin 1 Role of Prostaglandins and CRF. Annals of the New York Academy of Sciences, 1992, 650, 268-275.	3.8	57
292	Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences, 1992, 13, 24-28.	8.7	766
293	Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate social recognition in rat. Brain Research, 1992, 572, 261-264.	2.2	46
294	Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Research, 1992, 573, 318-320.	2.2	271
295	The macrophage-activating properties of growth hormone. Cellular and Molecular Neurobiology, 1992, 12, 499-510.	3.3	56
296	Behavioural effects of cytokines. , 1992, , 135-150.		14
297	Stress, stereotypies and welfare. Behavioural Processes, 1991, 25, 95-102.	1.1	77
298	Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor Î± in mice. European Journal of Pharmacology, 1991, 209, 281-283.	3.5	70
299	Androgen-dependent vasopressinergic neurotransmission attenuates interleukin-1-induced sickness behavior. Brain Research, 1991, 557, 115-120.	2.2	82
300	Behavioural effects of peripherally injected interleukin-1: role of prostaglandins. Brain Research, 1991, 542, 330-335.	2.2	136
301	Hypophysectomy Inhibits the Synthesis of Tumor Necrosis Factor Î± by Rat Macrophages: Partial Restoration by Exogenous Growth Hormone or Interferon Î³*. Endocrinology, 1991, 128, 989-996.	2.8	89
302	Role of Interferon-Î³ in Counteracting the Suppressive Effects of Transforming Growth Factor-Î²2 and Glucocorticoids on the Production of Tumor Necrosis Factor-Î±. Journal of Leukocyte Biology, 1990, 48, 473-481.	3.3	42
303	Animal suffering: The practical way forward. Behavioral and Brain Sciences, 1990, 13, 17-18.	0.7	5
304	Androgen-dependent vasopressinergic neurons are involved in social recognition in rats. Brain Research, 1990, 519, 150-157.	2.2	159
305	Social recognition does not involve vasopressinergic neurotransmission in female rats. Brain Research, 1990, 535, 301-304.	2.2	139
306	Cerebral lateralization of olfactory-mediated affective processes in rats. Behavioural Brain Research, 1990, 40, 53-60.	2.2	47

#	Article	IF	Citations
307	Neuroendocrine-Immune Interactions. Advances in Veterinary Medicine, 1990, 35, 283-305.	0.1	16
308	Role of neuropeptides in learning versus performance: Focus on vasopressin. Brain Research Bulletin, 1989, 23, 359-364.	3.0	40
309	Stress and immunity: An integrated view of relationships between the brain and the immune system. Life Sciences, 1989, 44, 1995-2008.	4.3	461
310	Septal vasopressin modulates social memory in male rats. Brain Research, 1988, 457, 143-147.	2.2	278
311	Interleukin-1 induces conditioned taste aversion in rats: a possible explanation for its pituitary-adrenal stimulating activity. Brain Research, 1988, 473, 369-371.	2.2	94
312	The Importance of Conditioning in Conditioned Immunosuppression. International Journal of Neuroscience, 1988, 39, 289-297.	1.6	2
313	Influence of stressor predictability and behavioral control on lymphocyte reactivity, antibody responses and neuroendocrine activation in rats. Physiology and Behavior, 1988, 43, 577-583.	2.1	99
314	Hypertonic saline mimics the effects of vasopressin on inhibitory avoidance in the rat. Behavioral and Neural Biology, 1987, 47, 130-137.	2.2	16
315	Frustration, Aggression and Drugs. Topics in the Neurosciences, 1987, , 1-13.	0.2	12
316	Behavioral Analysis of Anxiolytic Drug Action. , 1987, , 263-297.		5
317	Central injections of arginine vasopressin prolong extinction of active avoidance. Peptides, 1986, 7, 213-218.	2.4	46
318	Symposium on â€œIndices to Measure Animal Well-Beingâ€: Journal of Animal Science, 1986, 62, 1776-1786.	0.5	237
319	Is conditioned immunosuppression truly conditioned?. Behavioral and Brain Sciences, 1986, 9, 758-760.	0.7	36
320	Specificity of aversive stimulus properties of vasopressin. Psychopharmacology, 1985, 87, 238-241.	3.1	23
321	Osmotic stress mimics effects of vasopressin on learned behaviour. Nature, 1985, 315, 750-752.	27.8	46
322	Arginine Vasopressin, Stress, and Memory. Annals of the New York Academy of Sciences, 1985, 444, 194-202.	3.8	28
323	Analysis of the dual mechanism of ACTH release by arginine vasopressin and its analogs in conscious rats. Regulatory Peptides, 1985, 12, 175-184.	1.9	8
324	Stress in Domestic Animals: A Psychoneuroendocrine Approach. , 1985, , 81-95.		15

#	Article	IF	Citations
325	Relationship of the effects of the benzodiazepine derivative clorazepate on corticosterone secretion with its behavioural actions. Antagonism by ro 15â€“1788. Pharmacology Biochemistry and Behavior, 1984, 21, 839-843.	2.9	19
326	Behavioral effects of peripheral administration of arginine vasopressin: a review of our search for a mode of action and a hypothesis. Psychoneuroendocrinology, 1984, 9, 319-341.	2.7	93
327	De-arousal properties of stereotyped behaviour: Evidence from pituitaryâ€”Adrenal correlates in pigs. Applied Animal Ethology, 1983, 10, 233-244.	0.5	66
328	Stress in Farm Animals: A Need for Reevaluation. Journal of Animal Science, 1983, 57, 6-18.	0.5	376
329	Behavioural evidence for partial agonist properties of RO 15-1788, a benzodiazepine receptor antagonist. European Journal of Pharmacology, 1982, 81, 655-658.	3.5	120
330	Pituitary-adrenal consequences of adjunctive activities in pigs. Hormones and Behavior, 1981, 15, 386-395.	2.1	63
331	Conditioned taste aversion as an index of lead toxicity. Pharmacology Biochemistry and Behavior, 1980, 13, 133-135.	2.9	9
332	Effects of lithium on aggressive behaviour in domestic pigs. Journal of Veterinary Pharmacology and Therapeutics, 1979, 2, 299-303.	1.3	19
333	Antipunishment effects of diazepam: Interaction with shock and food deprivation levels in pigs. Psychopharmacology, 1978, 58, 99-104.	3.1	8
334	Pharmacokinetics of lithium in pigs. Journal of Veterinary Pharmacology and Therapeutics, 1978, 1, 309-312.	1.3	9
335	Dissociation between suppressive and facilitating effects of aversive stimuli on behavior by benzodiazepines. A review and reinterpretation. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1978, 2, 33-40.	0.6	14
336	Effects of diazepam on behaviour suppressed by extinction in pigs. Pharmacology Biochemistry and Behavior, 1977, 6, 157-161.	2.9	23
337	New aspects of the use of tranquillizers in animal husbandry, with particular reference to pigs. Veterinary Research Communications, 1977, 1, 161-169.	1.6	15
338	Neuroimmunology of Eating Disorders. , 0, , 1149-1157.		0
339	Inflammation, sickness behaviour and depression. , 0, , 265-279.		4
340	Neuroimmunological cross-talk in critical illness. , 0, , 160-171.		0
341	From inflammation to sickness and depression: the cytokine connection. , 0, , 95-109.		0